EIQ.AX is trading 34% up at A$1.67 amid a sharp speculative rally linked to expectations of an imminent U.S. FDA 510(k) decision for its EchoSolv-HF heart failure AI diagnostic tool.

  • The surge is driven by prior company guidance and strong validation data for the tool developed in collaboration with the Mayo Clinic.
  • Echo IQ has signaled expanded U.S. commercialization plans that are contingent on receiving the pending FDA clearance.